This month's edition of Drug Hunter's Molecules of the Month include Principia's reversible covalent BTK inhibitors and a single-dose antimalarial. Thanks to Bryan McKibben, Dennis Koester, Callie Bryan, and Christian Kuttruff for their nominations this month. To access our deep dives into the context, clinical development, mechanisms of action, hit-finding strategies, lead optimization, preclinical pharmacology, and more information and insights you won't find in the papers, subscribe to Premium.
Molecules of the Month
March 2022
- rilzabrutinib (PRN1008)
- INE963
- ulevostinag (MK-1454)
- compound 24
- compound 10
- etavopivat
- BMS-986176/LX-9211
- branaplam
- MAK683
- HR1405-01
Molecules of the Month
Molecules of the Month
Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!
Join the Drug Hunter Mailing List
to get free content and resources weekly. Trusted by >15,000 drug hunters worldwide. Unsubscribe anytime.
Popular Content
- 1.2023 Novel Small Molecule FDA Drug Approvals
- 2.Top 12 Most Popular Drug Hunter Case Studies of 2023
- 3.Top Ten Most Popular Drug Hunter Resources of 2023
- 4.Top 10 Most Popular Drug Hunter Review Articles of 2023
- 5.Practical PK Calculators
- 6.AACR Orlando 2023: New Drug Candidates
- 7.PK Cheat Sheet
- 8.Phase I Drug Metabolism
- 9.Why pKas Matter in Medicinal Chemistry and a Drug Discovery Amine pKa Table
- 10.Phase II Drug Metabolism
- 11.First Disclosures from ACS Chicago 2022
- 12.Topliss Tree and Topliss Scheme Posters
VIEW MORE CONTENT